Anika Therapeutics Inc. (NASDAQ:ANIK) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price target of $57.00 for the company and are forecasting that the company will post $0.54 EPS for the current quarter, according to Zacks. Zacks has also given Anika Therapeutics an industry rank of 107 out of 265 based on the ratings given to related companies.

A number of brokerages recently issued reports on ANIK. Barrington Research restated a “buy” rating and set a $57.00 price target on shares of Anika Therapeutics in a report on Thursday, December 28th. BidaskClub upgraded Anika Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th.

In other Anika Therapeutics news, CEO Charles H. Sherwood sold 3,293 shares of Anika Therapeutics stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $60.04, for a total transaction of $197,711.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Charles H. Sherwood sold 22,228 shares of Anika Therapeutics stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $60.06, for a total value of $1,335,013.68. Following the sale, the chief executive officer now directly owns 158,297 shares in the company, valued at $9,507,317.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,886 shares of company stock worth $2,606,455. Insiders own 6.57% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Stifel Financial Corp boosted its position in Anika Therapeutics by 16.3% during the 2nd quarter. Stifel Financial Corp now owns 163,694 shares of the biotechnology company’s stock valued at $8,076,000 after acquiring an additional 22,990 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Anika Therapeutics by 7.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 126,803 shares of the biotechnology company’s stock worth $6,257,000 after purchasing an additional 8,347 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Anika Therapeutics by 76.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 490,433 shares of the biotechnology company’s stock worth $24,199,000 after purchasing an additional 213,055 shares in the last quarter. Gotham Asset Management LLC boosted its position in shares of Anika Therapeutics by 49.2% in the 2nd quarter. Gotham Asset Management LLC now owns 33,826 shares of the biotechnology company’s stock worth $1,669,000 after purchasing an additional 11,162 shares in the last quarter. Finally, CS Mckee LP boosted its position in shares of Anika Therapeutics by 42.6% in the 3rd quarter. CS Mckee LP now owns 20,100 shares of the biotechnology company’s stock worth $1,166,000 after purchasing an additional 6,000 shares in the last quarter. 84.91% of the stock is currently owned by institutional investors and hedge funds.

Shares of Anika Therapeutics (ANIK) traded up $0.53 during trading hours on Thursday, reaching $56.03. The company had a trading volume of 65,601 shares, compared to its average volume of 52,700. Anika Therapeutics has a 52 week low of $41.64 and a 52 week high of $60.29. The stock has a market cap of $821.51, a P/E ratio of 26.31, a PEG ratio of 3.40 and a beta of 1.44.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.05. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. The company had revenue of $27.18 million for the quarter, compared to the consensus estimate of $27.44 million. During the same quarter in the previous year, the business earned $0.59 EPS. Anika Therapeutics’s revenue was up 5.4% compared to the same quarter last year. research analysts predict that Anika Therapeutics will post 1.9 EPS for the current year.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/1798167-2/1798167.html.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Get a free copy of the Zacks research report on Anika Therapeutics (ANIK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.